The role of regulatory T cells in the pathogenesis and treatment of prostate cancer.


Journal

Life sciences
ISSN: 1879-0631
Titre abrégé: Life Sci
Pays: Netherlands
ID NLM: 0375521

Informations de publication

Date de publication:
01 Nov 2021
Historique:
received: 10 12 2020
revised: 10 01 2021
accepted: 18 01 2021
pubmed: 30 1 2021
medline: 8 10 2021
entrez: 29 1 2021
Statut: ppublish

Résumé

Despite developments in the treatment of various cancers, prostate cancer is one of the deadliest diseases known to men. Systemic therapies such as androgen deprivation, chemotherapy, and radiation therapy have not been very successful in treating this disease. Numerous studies have shown that there is a direct relationship between cancer progression and inhibition of anti-tumor immune responses that can lead to progression of various malignancies, including prostate cancer. Interestingly, CD4

Identifiants

pubmed: 33513396
pii: S0024-3205(21)00117-X
doi: 10.1016/j.lfs.2021.119132
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

119132

Informations de copyright

Copyright © 2021. Published by Elsevier Inc.

Auteurs

Vahid Karpisheh (V)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Seyedeh Mahboubeh Mousavi (SM)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Parinaz Naghavi Sheykholeslami (P)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Mehrdad Fathi (M)

Cancer and Immunology Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran.

Mehran Mohammadpour Saray (M)

Department of Life Science Engineering, Faculty of New science and Technologies, University of Tehran, Tehran, Iran.

Leili Aghebati-Maleki (L)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Reza Jafari (R)

Solid Tumor Research Center, Cellular and Medicine Research Institute, Urmia University of Medical Sciences, Urmia, Iran.

Naime Majidi Zolbanin (N)

Department of Pharmacology and Toxicology, Faculty of Pharmacy, Urmia University of Medical Sciences, Urmia, Iran; Experimental and Applied Pharmaceutical Sciences Research Center, Urmia University of Medical Sciences, Urmia, Iran. Electronic address: majidiz.n@umsu.ac.ir.

Farhad Jadidi-Niaragh (F)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: jadidif@tbzmed.ac.ir.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH